COILED THERAPEUTICS PLC
COILED THERAPEUTICS PLC ORD 1P COIL.L · LSE
Live GBP 0.09 ▼ 0.00 (2.78%)
Mkt Cap £37.34M
Volume 266,640
52W 0.95 – 30.00
🔔 Sign in to receive sentiment alerts for COILED THERAPEUTICS PLC.
Market Sentiment
Sentiment Grade
A
↑ Improving (+8.9 pts vs 7-day avg)
COILED THERAPEUTICS PLC
Positive Sentiment
7.0/10
Sentiment Index
Very NegativeNeutralVery Positive
78%
Avg Confidence
58 / 0
Positive / Negative articles
📰 Based on 86 articles from 15 sources Proactive financial news ×21 Proactive Investors ×16 TradingView ×12 Yahoo Finance ×9 Yahoo Finance UK ×8
📊 Low volatility — MEVI 12.2/100
🕐 Updated 8 hours ago
📋 Today's context
Daily AI-generated context for this company — recent events, market backdrop, and supporting developments. Available to Pro Investor members.
Sentiment Distribution
Sentiment Trend
Latest RNS & Market News
- COILED THERAPEUTICS PLC – Change Of Registered OfficeRNS Number : 0004Q Coiled Therapeutics PLC 10 August 2026 10 August 2026 Coiled Therapeutics plc (“Coiled Therapeutics” or the “Company”) Change of Registered Office Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, announces that, with immediate effect, the registered…
- COILED THERAPEUTICS PLC – First Patient Dosed With New Formulation Of Ao 252RNS Number : 8752O Coiled Therapeutics PLC 03 August 2026 3 August 2026 Coiled Therapeutics plc (“Coiled Therapeutics” or the “Company”) First Patient Dosed with Optimised Lipid-Based Formulation of AO-252 Refined oral formulation designed to optimise drug exposure ahead of planned Phase I/II dose expansion in ovarian and prostate cancer Coiled Therapeutics…
- COILED THERAPEUTICS PLC – Coiled Advances Next Generation Ao 252 FormulationRNS Number : 2229L Coiled Therapeutics PLC 07 July 2026 7 July 2026 Coiled Therapeutics plc (“Coiled Therapeutics” or the “Company”) Company Advances Next-Generation AO-252 Formulation Lipid-Based Softgel Designed to Optimise Drug Exposure Ahead of Dose Expansion Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers,…
- COILED THERAPEUTICS PLC – Appointment Of Independent Non Executive DirectorRNS Number : 4574J Coiled Therapeutics PLC 24 June 2026 24 June 2026 Coiled Therapeutics plc (“Coiled Therapeutics” or the “Company”) Appointment of Independent Non-Executive Director Seasoned biotech and capital markets leader joins the Board Coiled Therapeutics (AIM: COIL) (OTCQB: COTFX), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces…